{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-129007","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2023-12-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.166587+00:00","generated_at":"2026-06-07T07:17:20.329304+00:00","sec_items":["8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Immunome to acquire Atreca antibody assets for $5.5M upfront plus up to $7M milestones","bullets":["Upfront cash payment of $5.5 million; additional $7.0 million in clinical development milestones.","Assets include certain antibody-related assets and materials from Atreca, Inc.","Transaction subject to customary conditions and Atreca stockholder approval.","Immunome expects to expand its pipeline with the acquired assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-129007","json":"https://secwatch.observer/filing/0001104659-23-129007.json","markdown":"https://secwatch.observer/filing/0001104659-23-129007.md","text":"https://secwatch.observer/filing/0001104659-23-129007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923129007/0001104659-23-129007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465923129007/tm2333682d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T07:17:20.329304+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}